Setting the benchmark for tailoring treatment with EGFR tyrosine kinase inhibitors

Author： Rosell Rafael   Taron Miquel   Sanchez Jose Javier   Paz-Ares Luis  

Publisher： Future Medicine

ISSN： 1479-6694

Source： Future Oncology, Vol.3, Iss.3, 2007-06, pp. : 277-283

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme

By Raizer Jeffrey  

Journal of Neuro-Oncology, Vol. 74, Iss. 1, 2005-08 ,pp. : 77-86

Springer Publishing Company

Access to resources Recommend Favorite

Clinical development of EGFR-tyrosine kinase inhibitors in Japan

By Nakagawa Kazuhiko  

Cancer Chemotherapy and Pharmacology, Vol. 58, Iss. 1, 2006-11 ,pp. : 33-37

Springer Publishing Company

Access to resources Recommend Favorite

Clinical development of EGFR-tyrosine kinase inhibitors in Japan

By Nakagawa Kazuhiko  

Cancer Chemotherapy and Pharmacology, Vol. 58, Iss. 7, 2006-11 ,pp. : 33-37

Springer Publishing Company

Access to resources Recommend Favorite

Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 9, Iss. 8, 2009-10 ,pp. : 853-863

Bentham Science Publishers

Access to resources Recommend Favorite

Impact of EGFR tyrosine kinase inhibitors versus chemotherapy on the development of leptomeningeal metastasis in never smokers with advanced adenocarcinoma of the lung

By Lee Youngjoo   Han Ji-Youn   Kim Heung   Yun Tak   Lee Geon   Kim Hyae   Lee Jin  

Journal of Neuro-Oncology, Vol. 115, Iss. 1, 2013-10 ,pp. : 95-101

Springer Publishing Company

Access to resources Recommend Favorite